The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Noninvasive Prenatal Diagnostics-Global Market Insights and Sales Trends 2024
Synopsis
Noninvasive Prenatal Diagnostics detect a variety of chromosomal disorders such as Down's syndrome, Edwards syndrome, Turner syndrome and Pato syndrome.
The global Noninvasive Prenatal Diagnostics market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Noninvasive Prenatal Diagnostics in various end use industries. The expanding demands from the Hospital, Personal and Other,, are propelling Noninvasive Prenatal Diagnostics market. Services, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Instrument segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Noninvasive Prenatal Diagnostics, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Noninvasive Prenatal Diagnostics market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Noninvasive Prenatal Diagnostics market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Noninvasive Prenatal Diagnostics sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Noninvasive Prenatal Diagnostics covered in this report include Natera, Illumina, BGI Diagnosis, Ariosa Diagnostics, Quest Diagnostics, Premaitha Health, NIPD Genetics, Labcorp and Ravgen, etc.
The global Noninvasive Prenatal Diagnostics market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Natera
Illumina
BGI Diagnosis
Ariosa Diagnostics
Quest Diagnostics
Premaitha Health
NIPD Genetics
Labcorp
Ravgen
LifeCodexx
TrovaGene
Quest Diagnostics
Berry Genomics
Global Noninvasive Prenatal Diagnostics market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Noninvasive Prenatal Diagnostics market, Segment by Type:
Services
Instrument
Global Noninvasive Prenatal Diagnostics market, by Application
Hospital
Personal
Other
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Noninvasive Prenatal Diagnostics companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Noninvasive Prenatal Diagnostics detect a variety of chromosomal disorders such as Down's syndrome, Edwards syndrome, Turner syndrome and Pato syndrome.
The global Noninvasive Prenatal Diagnostics market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Noninvasive Prenatal Diagnostics in various end use industries. The expanding demands from the Hospital, Personal and Other,, are propelling Noninvasive Prenatal Diagnostics market. Services, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Instrument segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Noninvasive Prenatal Diagnostics, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Noninvasive Prenatal Diagnostics market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Noninvasive Prenatal Diagnostics market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Noninvasive Prenatal Diagnostics sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Noninvasive Prenatal Diagnostics covered in this report include Natera, Illumina, BGI Diagnosis, Ariosa Diagnostics, Quest Diagnostics, Premaitha Health, NIPD Genetics, Labcorp and Ravgen, etc.
The global Noninvasive Prenatal Diagnostics market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Natera
Illumina
BGI Diagnosis
Ariosa Diagnostics
Quest Diagnostics
Premaitha Health
NIPD Genetics
Labcorp
Ravgen
LifeCodexx
TrovaGene
Quest Diagnostics
Berry Genomics
Global Noninvasive Prenatal Diagnostics market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Noninvasive Prenatal Diagnostics market, Segment by Type:
Services
Instrument
Global Noninvasive Prenatal Diagnostics market, by Application
Hospital
Personal
Other
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Noninvasive Prenatal Diagnostics companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Noninvasive Prenatal Diagnostics
1.1 Noninvasive Prenatal Diagnostics Market Overview
1.1.1 Noninvasive Prenatal Diagnostics Product Scope
1.1.2 Noninvasive Prenatal Diagnostics Market Status and Outlook
1.2 Global Noninvasive Prenatal Diagnostics Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Noninvasive Prenatal Diagnostics Market Size by Region (2018-2029)
1.4 Global Noninvasive Prenatal Diagnostics Historic Market Size by Region (2018-2023)
1.5 Global Noninvasive Prenatal Diagnostics Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Noninvasive Prenatal Diagnostics Market Size (2018-2029)
1.6.1 North America Noninvasive Prenatal Diagnostics Market Size (2018-2029)
1.6.2 Europe Noninvasive Prenatal Diagnostics Market Size (2018-2029)
1.6.3 Asia-Pacific Noninvasive Prenatal Diagnostics Market Size (2018-2029)
1.6.4 Latin America Noninvasive Prenatal Diagnostics Market Size (2018-2029)
1.6.5 Middle East & Africa Noninvasive Prenatal Diagnostics Market Size (2018-2029)
2 Noninvasive Prenatal Diagnostics Market by Type
2.1 Introduction
2.1.1 Services
2.1.2 Instrument
2.2 Global Noninvasive Prenatal Diagnostics Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Noninvasive Prenatal Diagnostics Historic Market Size by Type (2018-2023)
2.2.2 Global Noninvasive Prenatal Diagnostics Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Noninvasive Prenatal Diagnostics Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Noninvasive Prenatal Diagnostics Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Noninvasive Prenatal Diagnostics Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Noninvasive Prenatal Diagnostics Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Noninvasive Prenatal Diagnostics Revenue Breakdown by Type (2018-2029)
3 Noninvasive Prenatal Diagnostics Market Overview by Application
3.1 Introduction
3.1.1 Hospital
3.1.2 Personal
3.1.3 Other
3.2 Global Noninvasive Prenatal Diagnostics Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Noninvasive Prenatal Diagnostics Historic Market Size by Application (2018-2023)
3.2.2 Global Noninvasive Prenatal Diagnostics Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Noninvasive Prenatal Diagnostics Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Noninvasive Prenatal Diagnostics Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Noninvasive Prenatal Diagnostics Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Noninvasive Prenatal Diagnostics Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Noninvasive Prenatal Diagnostics Revenue Breakdown by Application (2018-2029)
4 Noninvasive Prenatal Diagnostics Competition Analysis by Players
4.1 Global Noninvasive Prenatal Diagnostics Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Noninvasive Prenatal Diagnostics as of 2022)
4.3 Date of Key Players Enter into Noninvasive Prenatal Diagnostics Market
4.4 Global Top Players Noninvasive Prenatal Diagnostics Headquarters and Area Served
4.5 Key Players Noninvasive Prenatal Diagnostics Product Solution and Service
4.6 Competitive Status
4.6.1 Noninvasive Prenatal Diagnostics Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Natera
5.1.1 Natera Profile
5.1.2 Natera Main Business
5.1.3 Natera Noninvasive Prenatal Diagnostics Products, Services and Solutions
5.1.4 Natera Noninvasive Prenatal Diagnostics Revenue (US$ Million) & (2018-2023)
5.1.5 Natera Recent Developments
5.2 Illumina
5.2.1 Illumina Profile
5.2.2 Illumina Main Business
5.2.3 Illumina Noninvasive Prenatal Diagnostics Products, Services and Solutions
5.2.4 Illumina Noninvasive Prenatal Diagnostics Revenue (US$ Million) & (2018-2023)
5.2.5 Illumina Recent Developments
5.3 BGI Diagnosis
5.3.1 BGI Diagnosis Profile
5.3.2 BGI Diagnosis Main Business
5.3.3 BGI Diagnosis Noninvasive Prenatal Diagnostics Products, Services and Solutions
5.3.4 BGI Diagnosis Noninvasive Prenatal Diagnostics Revenue (US$ Million) & (2018-2023)
5.3.5 Ariosa Diagnostics Recent Developments
5.4 Ariosa Diagnostics
5.4.1 Ariosa Diagnostics Profile
5.4.2 Ariosa Diagnostics Main Business
5.4.3 Ariosa Diagnostics Noninvasive Prenatal Diagnostics Products, Services and Solutions
5.4.4 Ariosa Diagnostics Noninvasive Prenatal Diagnostics Revenue (US$ Million) & (2018-2023)
5.4.5 Ariosa Diagnostics Recent Developments
5.5 Quest Diagnostics
5.5.1 Quest Diagnostics Profile
5.5.2 Quest Diagnostics Main Business
5.5.3 Quest Diagnostics Noninvasive Prenatal Diagnostics Products, Services and Solutions
5.5.4 Quest Diagnostics Noninvasive Prenatal Diagnostics Revenue (US$ Million) & (2018-2023)
5.5.5 Quest Diagnostics Recent Developments
5.6 Premaitha Health
5.6.1 Premaitha Health Profile
5.6.2 Premaitha Health Main Business
5.6.3 Premaitha Health Noninvasive Prenatal Diagnostics Products, Services and Solutions
5.6.4 Premaitha Health Noninvasive Prenatal Diagnostics Revenue (US$ Million) & (2018-2023)
5.6.5 Premaitha Health Recent Developments
5.7 NIPD Genetics
5.7.1 NIPD Genetics Profile
5.7.2 NIPD Genetics Main Business
5.7.3 NIPD Genetics Noninvasive Prenatal Diagnostics Products, Services and Solutions
5.7.4 NIPD Genetics Noninvasive Prenatal Diagnostics Revenue (US$ Million) & (2018-2023)
5.7.5 NIPD Genetics Recent Developments
5.8 Labcorp
5.8.1 Labcorp Profile
5.8.2 Labcorp Main Business
5.8.3 Labcorp Noninvasive Prenatal Diagnostics Products, Services and Solutions
5.8.4 Labcorp Noninvasive Prenatal Diagnostics Revenue (US$ Million) & (2018-2023)
5.8.5 Labcorp Recent Developments
5.9 Ravgen
5.9.1 Ravgen Profile
5.9.2 Ravgen Main Business
5.9.3 Ravgen Noninvasive Prenatal Diagnostics Products, Services and Solutions
5.9.4 Ravgen Noninvasive Prenatal Diagnostics Revenue (US$ Million) & (2018-2023)
5.9.5 Ravgen Recent Developments
5.10 LifeCodexx
5.10.1 LifeCodexx Profile
5.10.2 LifeCodexx Main Business
5.10.3 LifeCodexx Noninvasive Prenatal Diagnostics Products, Services and Solutions
5.10.4 LifeCodexx Noninvasive Prenatal Diagnostics Revenue (US$ Million) & (2018-2023)
5.10.5 LifeCodexx Recent Developments
5.11 TrovaGene
5.11.1 TrovaGene Profile
5.11.2 TrovaGene Main Business
5.11.3 TrovaGene Noninvasive Prenatal Diagnostics Products, Services and Solutions
5.11.4 TrovaGene Noninvasive Prenatal Diagnostics Revenue (US$ Million) & (2018-2023)
5.11.5 TrovaGene Recent Developments
5.12 Quest Diagnostics
5.12.1 Quest Diagnostics Profile
5.12.2 Quest Diagnostics Main Business
5.12.3 Quest Diagnostics Noninvasive Prenatal Diagnostics Products, Services and Solutions
5.12.4 Quest Diagnostics Noninvasive Prenatal Diagnostics Revenue (US$ Million) & (2018-2023)
5.12.5 Quest Diagnostics Recent Developments
5.13 Berry Genomics
5.13.1 Berry Genomics Profile
5.13.2 Berry Genomics Main Business
5.13.3 Berry Genomics Noninvasive Prenatal Diagnostics Products, Services and Solutions
5.13.4 Berry Genomics Noninvasive Prenatal Diagnostics Revenue (US$ Million) & (2018-2023)
5.13.5 Berry Genomics Recent Developments
6 North America
6.1 North America Noninvasive Prenatal Diagnostics Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Noninvasive Prenatal Diagnostics Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Noninvasive Prenatal Diagnostics Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Noninvasive Prenatal Diagnostics Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Noninvasive Prenatal Diagnostics Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Noninvasive Prenatal Diagnostics Market Dynamics
11.1 Noninvasive Prenatal Diagnostics Industry Trends
11.2 Noninvasive Prenatal Diagnostics Market Drivers
11.3 Noninvasive Prenatal Diagnostics Market Challenges
11.4 Noninvasive Prenatal Diagnostics Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
